Trial Profile
Intravitreal Bevacizumab (AvastinTM) Injections Versus Conventional Laser Surgery for Vision-threatening Retinopathy of Prematurity: a Prospective, Randomized, Non-blinded, Controlled, Multi-center, Clinical Trial
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 21 Jul 2022
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Retinopathy of prematurity
- Focus Therapeutic Use
- Acronyms BEAT-ROP
- 21 Feb 2016 Planned End Date changed from 1 Oct 2017 to 1 Aug 2020 as per ClinicalTrials.gov record.
- 18 Sep 2015 New trial record